WPP Group PLC
9 May 2001
FOR IMMEDIATE RELEASE 9 May 2001
WPP GROUP PLC ('WPP')
Acquires US pharmaceutical research group, Ziment
WPP announces that its wholly-owned information and consultancy division,
Kantar, has acquired 100% of Ziment Associates Inc. and affiliated companies
('Ziment'), a leading US-based pharmaceutical research group.
Founded in 1976 and headquartered in New York, Ziment employs 135 people in
its five operating units across 11 offices in the US. Ziment's clients
include some of the world's largest pharmaceutical and biotechnology
companies.
Ziment will form the core of a new global healthcare practice to improve
further the service Kantar offers its pharmaceutical, biotechnology and
medical device clients. Other WPP companies in the healthcare communications
sector include CommonHealth and Sudler & Hennessey, two of the world's largest
pharmaceutical marketing and communications businesses.
Ziment had revenues of $18.8 million for the year 2000 and net assets of $4.2
million as at 31 December 2000.
The acquisition of Ziment continues WPP's strategy of establishing a
leadership position in fast-growing sectors and important markets.
Further information:
Feona McEwan, WPP
Tel +44-20 7408 2204
www.wpp.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.